Broadwing Bio
PrivateLast Round
Convertible Debt
Feb 2, 2024
Total Funding Raised
$9.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Broadwing Bio operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Convertible Debt round in February 2024.
Broadwing Bio is a biotechnology company that develops targeted antibody therapies for the treatment of ophthalmic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Broadwing Bio Comparables
Compare Broadwing Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Galimedix Therapeutics | 79% | |
| Annexon Biosciences | 77% | |
| ONL Therapeutics | 74% |
For institutional investors. Book with your work email.
Broadwing Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Feb 2, 2024 | ||||
| Corporate Funding | Dec 7, 2020 |
For institutional investors. Book with your work email.
Broadwing Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Echo Investment Capital | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 238% MoM.
- Feb 2, 2024
$10M raised from Echo Investment Capital and others.
For institutional investors. Book with your work email.
Broadwing Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Broadwing Bio's valuation, stock price, and market status.
Is Broadwing Bio a public or private company?
Broadwing Bio is a private company.
What is the current stock price of Broadwing Bio?
Broadwing Bio is a private company, so its shares have no public market price. Caplight tracks Broadwing Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Broadwing Bio worth (valuation)?
Valuation information for Broadwing Bio is not publicly available.
Can I buy Broadwing Bio stock?
Broadwing Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Broadwing Bio's last funding round?
Broadwing Bio's most recent funding round was Convertible Debt on February 2, 2024.
Who are the main investors in Broadwing Bio?
Key investors in Broadwing Bio include Echo Investment Capital.
Will Broadwing Bio IPO soon?
No public IPO plans have been announced for Broadwing Bio.
How can I track Broadwing Bio secondary market activity?
Caplight tracks bids, offers, and trades in Broadwing Bio's shares on secondary markets.